The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information:

Study Name on (link is external)
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis
Study DrugGalicaftor/Navocaftor/ABBV-119
Type of Study DrugCFTR Modulation
Study TitleA Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Study Phase2
Study SponsorAbbvie

Link on (link is external) 

Participating ECFS-CTN sitesPlease contact for most recent sitelist
AgeAdult patients